Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Biomarkers provide a dynamic and powerful approach to understanding the spectrum of diseases from the earliest manifestations to the terminal stages. A recently published framework for the diagnosis of Alzheimer’s Disease (AD) in research studies would allow diagnosis on the sole basis of two biomarkers (b-amyloid and tau). This revision will have substantial implications for future Alzheimer’s research. We will discuss the conditions that need to be met (validity, reliability, innovation) for this new diagnostic framework to foster identification of effective strategies to prevent or treat AD.